January 20, 2020

Medtronic’s new DBS software aims for more personalised treatment of Movement Disorders like Dystonia

Medtronic Receives CE (Conformité Européenne) Mark Approval for the Percept™ PC Neurostimulator DBS System with BrainSense™ Technology. This new system can sense and record brain signals while delivering therapy to patients with neurologic disorders, such as Dystonia. This enables physicians to deliver more data-driven, personal neurostimulation treatment. The neurostimulator has been approved in the EU…

Show this Post ›
December 18, 2019

Predicting Antidystonic Effects of Deep Brain Stimulation (DBS) Using Probabilistic Maps

The following article, makes reference to certain companies and their products and any opinions expressed should not be taken to be the views of Dystonia Europe or its members.  The articles are written by respected authors and are provided for the information of Dystonia Europe News readers. Deep Brain Stimulation (DBS) is an established therapy…

Show this Post ›
December 11, 2019

Dystonia Patient Leaders Discuss Importance of Research and the Samuel Belzberg 6th International Dystonia Symposium

On June 4-6, 2020 the Samuel Belzberg 6th International Dystonia Symposium (IDS6) will take place in Dublin, Ireland.  This Symposium represents the latest chapter in a definitive series of international dystonia meetings held since 1975 to bring together experts to present and discuss the latest information on dystonia. The Symposium is being organized by the…

Show this Post ›
December 11, 2019

Professor Pisani Receives The Bachmann-Strauss Prize for Excellence in Dystonia Research 2019

Dystonia is a distinct movement disorder, a clinical entity determined by genetic and environmental factors. However, dystonia is commonly found as a disabling symptom of Parkinson’s disease. Indeed, up to 30% of Parkinson’s patients can exhibit dystonia as a presenting symptom, or even as a motor complication during the course of the disease. Since 2014,…

Show this Post ›